–Dendreon: Healthy Competition Will Boost Profits@ Dividend Kings
-more coming soon
About Dendreon Corporation (DNDN)
Dendreon Corporation (DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. Dendreon’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE (sipuleucel-T), is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates it has under development include investigational cellular immunotherapies targeted towards HER2/neu for the treatment of patients with bladder, breast, ovarian and other solid tumors, carbonic anhydrase 9 (CA9), and carcinoembryonic antigen (CEA). In December 2012, the Company sold its immunotherapy manufacturing facility (IMF).
Dendreon Corporation (DNDN)